Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics closed a private placement raising $8.5 million upfront with up to $15.2 million in potential additional proceeds from warrant exercises. The company plans to use net proceeds for FDA approval efforts, R&D activities, and working capital, with cash runway expected to extend into Q1 2027 and potentially beyond FDA approval if warrants are fully exercised.